Novo Nordisk Shares Dip 7.4%
Photo: Johan Nilsson / TT

Novo Nordisk Shares Dip 7.4% After Rival Drug Study Results

Advertisement

The Danish pharmaceutical giant Novo Nordisk plummeted by around ten percent on the Copenhagen Stock Exchange, but recovered somewhat and closed at minus 7.4 percent.

The reason for the setback is primarily new drug studies from the competitor, American Eli Lilly. Both companies are giants in weight loss medication. The study shows that Eli Lilly's pills have approximately the same effect as Novo's preparation Ozempic.

The previously successful stock Novo Nordisk has lost around a third of its stock market value since the turn of the year.

AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All